
TELA Bio, Inc.
- Jurisdiction
United States - ISIN
US8723811084 (TELA )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Read full profile
Fundamentals
- Net revenue
€64.25M - Gross margin
67.3% - EBIT
-€31.79M - EBIT margin
-49.5% - Net income
-€34.77M - Net margin
-54.1%
Statement period: - (published )
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Sell |
Earnings Calls
Latest earnings call: May 9, 2024 (Q1 2024)